File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Lansoprazole But Not Rofecoxib Reduced Dyspeptic Symptoms of Patients on NSAIDs

TitleLansoprazole But Not Rofecoxib Reduced Dyspeptic Symptoms of Patients on NSAIDs
Authors
Issue Date2005
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
Digestive Disease Week, Chicago, IL, 14-19 May 2005. In Gastroenterology, 2005, v. 128 n. 4 S2, p. A-24 How to Cite?
AbstractPurpose: To investigate the efficacy of lansoprazole co-therapy or rofecoxib in the reduction of dyspeptic symptoms in patients taking continuous non-steroidal anti-inflammatory drugs (NSAIDs). Methods: Patients (aged 18 years) who developed dyspepsia (upper abdominal discomfort) while taking daily continuous NSAIDs were screened for the study. Upper endoscopy was performed and patients without baseline peptic ulcers were recruited into the study. They were randomized to receive rofecoxib 25 mg, lansoprazole 30 mg plus diclofenac 100 mg or diclofenac 100mg orally, once daily for 4 weeks. All medications were packed in matched capsules to ensure double-blinding of the study. Dyspeptic symptoms were assessed after 2 weeks and 4 weeks and were graded according to a five-point Likert scale (none, mild, moderate, severe and very severe). The primary endpoint was the proportion of patients who had persistent moderate to severe dyspeptic symptoms. Results: A total of 189 patients were randomized into the study. At the end of 4 weeks, significantly fewer patients receiving diclofenac and lansoprazole had persistent dyspeptic symptoms than patients receiving diclofenac alone (9/64, 14.1% vs 24/62, 37.1%; p0.002). On the other hand, there was no difference in persistent dyspeptic symptoms between patients receiving rofecoxib and patients receiving diclofenac (18/63, 28.6% vs 24/62, 37.1%; p0.26). Conclusion: Lansoprazole co-therapy, but not rofecoxib, effectively controls dyspeptic symptoms associated with long term continuous NSAIDs use.
Persistent Identifierhttp://hdl.handle.net/10722/102185
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170

 

DC FieldValueLanguage
dc.contributor.authorLai, KCen_HK
dc.contributor.authorHui, WMen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorHu, HCen_HK
dc.contributor.authorChan, OOen_HK
dc.contributor.authorLam, SKen_HK
dc.date.accessioned2010-09-25T20:20:27Z-
dc.date.available2010-09-25T20:20:27Z-
dc.date.issued2005en_HK
dc.identifier.citationDigestive Disease Week, Chicago, IL, 14-19 May 2005. In Gastroenterology, 2005, v. 128 n. 4 S2, p. A-24en_HK
dc.identifier.issn0016-5085en_HK
dc.identifier.urihttp://hdl.handle.net/10722/102185-
dc.description.abstractPurpose: To investigate the efficacy of lansoprazole co-therapy or rofecoxib in the reduction of dyspeptic symptoms in patients taking continuous non-steroidal anti-inflammatory drugs (NSAIDs). Methods: Patients (aged 18 years) who developed dyspepsia (upper abdominal discomfort) while taking daily continuous NSAIDs were screened for the study. Upper endoscopy was performed and patients without baseline peptic ulcers were recruited into the study. They were randomized to receive rofecoxib 25 mg, lansoprazole 30 mg plus diclofenac 100 mg or diclofenac 100mg orally, once daily for 4 weeks. All medications were packed in matched capsules to ensure double-blinding of the study. Dyspeptic symptoms were assessed after 2 weeks and 4 weeks and were graded according to a five-point Likert scale (none, mild, moderate, severe and very severe). The primary endpoint was the proportion of patients who had persistent moderate to severe dyspeptic symptoms. Results: A total of 189 patients were randomized into the study. At the end of 4 weeks, significantly fewer patients receiving diclofenac and lansoprazole had persistent dyspeptic symptoms than patients receiving diclofenac alone (9/64, 14.1% vs 24/62, 37.1%; p0.002). On the other hand, there was no difference in persistent dyspeptic symptoms between patients receiving rofecoxib and patients receiving diclofenac (18/63, 28.6% vs 24/62, 37.1%; p0.26). Conclusion: Lansoprazole co-therapy, but not rofecoxib, effectively controls dyspeptic symptoms associated with long term continuous NSAIDs use.-
dc.languageengen_HK
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastroen_HK
dc.relation.ispartofGastroenterologyen_HK
dc.titleLansoprazole But Not Rofecoxib Reduced Dyspeptic Symptoms of Patients on NSAIDsen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0016-5085&volume=128&issue=4 Suppl 2&spage=A24&epage=&date=2005&atitle=Lansorprazole+but+not+Rofecoxib+reduced+dyspeptic+symptoms+of+patients+on+NSAIDSen_HK
dc.identifier.emailLai, KC: kclai@HKUCC.hku.hken_HK
dc.identifier.emailHui, WM: hrmehwm@hkucc.hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.emailHu, HC: hchu@HKUCC.hku.hken_HK
dc.identifier.emailChan, OO: aoochan@hku.hken_HK
dc.identifier.emailLam, SK: deanmed@hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1053/j.gastro.2005.04.003-
dc.identifier.hkuros99428en_HK
dc.identifier.volume128en_HK
dc.identifier.issue4 Suppl 2en_HK
dc.identifier.spage24en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats